These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8327652)

  • 41. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
    Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
    Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
    Alban S; Gastpar R
    Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of low dose nitroglycerin on plasma heparin concentrations and activated partial thromboplastin times.
    Brack MJ; More RS; Hubner PJ; Gershlick AH
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):183-6. PubMed ID: 8457649
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The observation of heparin on endothelium after injection.
    Hiebert LM; Jaques LB
    Thromb Res; 1976 Feb; 8(2):195-204. PubMed ID: 1251350
    [No Abstract]   [Full Text] [Related]  

  • 45. In vivo antithrombotic synergy of oral heparin and arginine: endothelial thromboresistance without changes in coagulation parameters.
    Daniels B; Linhardt RJ; Zhang F; Mao W; Wice SM; Hiebert LM
    Thromb Haemost; 2006 May; 95(5):865-72. PubMed ID: 16676079
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Organ glycosaminoglycan distribution after intravenous and oral administration in rats.
    Marchi E; Barbanti M; Milani R; Breccia A; Fini A; Gattavecchia E
    Semin Thromb Hemost; 1994; 20(3):297-300. PubMed ID: 7824965
    [No Abstract]   [Full Text] [Related]  

  • 47. Inactivation of thrombin by the aortic endothelium.
    Swedenborg J; Dryjski M; Olsson P
    Thromb Haemost; 1983 Oct; 50(3):635-8. PubMed ID: 6648887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and distribution of heparin-binding growth factor I (endothelial cell growth factor) in the rat.
    Rosengart TK; Kuperschmid JP; Maciag T; Clark RE
    Circ Res; 1989 Feb; 64(2):227-34. PubMed ID: 2463884
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Distribution of heparin and its complex compounds in the tissues of animals maintained on an atherogenic diet following intravenous administration of a thromboplastin-heparin complex].
    Ul'ianov AM; Liapina LA; Bazaz'ian GG; Boneva ZhS
    Vopr Med Khim; 1981; 27(4):458-62. PubMed ID: 7293076
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug prophylaxis in atherosclerosis.
    Jaques LB
    Artery; 1987; 14(4):209-15. PubMed ID: 2441684
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The study of the effect of thiazoline ammonium 4-chlorophenyl-2-hydroxy-4-oxo-2-butenoate on blood coagulation upon intragastric and subcutaneous administration.
    Starkova AV; Sobin FV; Syropyatov BY; Pulina NA
    Bull Exp Biol Med; 2014 Nov; 158(1):46-8. PubMed ID: 25403395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose-dependent plasma elimination of subcutaneously administered calcium heparin in horses.
    Gerhards H; Kietzmann M
    J Vet Pharmacol Ther; 1988 Mar; 11(1):77-83. PubMed ID: 3379667
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A quest for the relief of atherosclerosis: potential role of intrapulmonary heparin--a hypothesis.
    Kanabrocki EL; Bremner WF; Sothern RB; Gruber SA; Third JL; Bushnell DL; Olwin JH
    Q J Med; 1992 Apr; 83(300):259-82. PubMed ID: 1631260
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dose-dependent uptake of radioactivity by liver parenchymal and non-parenchymal cells after intravenous administration of fractionated 3H-heparin to rats.
    Watanabe J; Haba M; Muranishi H; Yuasa H
    Biol Pharm Bull; 1993 Oct; 16(10):1031-4. PubMed ID: 8287033
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vascular distribution of intratracheally administered heparin.
    Mahadoo J; Hiebert LM; Wright CJ; Jaques LB
    Ann N Y Acad Sci; 1981; 370():650-5. PubMed ID: 7023328
    [No Abstract]   [Full Text] [Related]  

  • 56. Intrapulmonary heparin. A new procedure for anticoagulant therapy.
    Jaques LB; Mahadoo J; Kavanagh LW
    Lancet; 1976 Nov; 2(7996):1157-61. PubMed ID: 62993
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tissue average binding and equilibrium distribution: an example with heparin in arterial tissues.
    Lovich MA; Edelman ER
    Biophys J; 1996 Mar; 70(3):1553-9. PubMed ID: 8785313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Binding of low-molecular-weight heparin to aortic endothelium in rabbits.
    Gensini GF; Fortini A; Lombardi A; Pesciullesi E; Pieroni C; Neri Serneri GG
    Haemostasis; 1984; 14(6):466-72. PubMed ID: 6534819
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasma heparin levels after administration of calcium and sodium salts of heparin.
    Thomas DP; Sagar S; Stamatakis JD; Maffei FH; Erdi A; Kakkar VV
    Thromb Res; 1976 Sep; 9(3):241-8. PubMed ID: 790636
    [No Abstract]   [Full Text] [Related]  

  • 60. [Experimental study of the disappearance rate of plasma heparin after an intravenous injection].
    Weiss M
    Hemostase; 1966; 6(2):149-66. PubMed ID: 5955738
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.